Dynamics of the Cellular and Humoral Immune Response After BNT162b2 Messenger Ribonucleic Acid Coronavirus Disease 2019 (COVID-19) Vaccination in COVID-19-Naive Nursing Home Residents

J Infect Dis. 2021 Nov 22;224(10):1690-1693. doi: 10.1093/infdis/jiab458.

Abstract

Short-term humoral and cellular immune responses are diminished after BNT162b2 messenger ribonucleic acid coronavirus disease 2019 (COVID-19) vaccination in COVID-19-naive nursing home residents, a population particularly vulnerable to the disease. We found both responses to decline after 4 weeks and remain lower than those of healthcare workers after 24 weeks, with an estimated half-life of the antibody response of 47 days. At 4 weeks, older age was significantly associated with a decreased humoral response, and diabetes mellitus and active malignancy were associated with a decreased cellular response. Our results imply that COVID-19-naive nursing home residents are a target group for booster vaccination trials.

Keywords: 19; 19 vaccine; 2; BNT162b2 mRNA COVID; COVID; CoV; SARS; nursing home residents.

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • Humans
  • Immunity, Humoral*
  • Nursing Homes
  • RNA
  • Vaccination

Substances

  • Antibodies, Viral
  • RNA
  • BNT162 Vaccine